414 related articles for article (PubMed ID: 25483677)
1. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
2. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
Wurz GT; Gutierrez AM; Greenberg BE; Vang DP; Griffey SM; Kao CJ; Wolf M; DeGregorio MW
J Transl Med; 2013 Mar; 11():64. PubMed ID: 23496860
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
[TBL] [Abstract][Full Text] [Related]
5. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
[TBL] [Abstract][Full Text] [Related]
6. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
[TBL] [Abstract][Full Text] [Related]
7. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
[TBL] [Abstract][Full Text] [Related]
8. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.
Mitchell P; Thatcher N; Socinski MA; Wasilewska-Tesluk E; Horwood K; Szczesna A; Martín C; Ragulin Y; Zukin M; Helwig C; Falk M; Butts C; Shepherd FA
Ann Oncol; 2015 Jun; 26(6):1134-1142. PubMed ID: 25722382
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
Kao CJ; Wurz GT; Monjazeb AM; Vang DP; Cadman TB; Griffey SM; Wolf M; DeGregorio MW
Cancer Immunol Res; 2014 Jun; 2(6):581-9. PubMed ID: 24894093
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
12. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
[TBL] [Abstract][Full Text] [Related]
13. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
Hong S; Qian J; Li H; Yang J; Lu Y; Zheng Y; Yi Q
Cancer Immunol Immunother; 2012 Apr; 61(4):561-71. PubMed ID: 22002243
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
[TBL] [Abstract][Full Text] [Related]
15. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
Ocadlíková D; Kovárová L; Hájek R; Michálek J
Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
[TBL] [Abstract][Full Text] [Related]
16. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
17. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M;
Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419
[TBL] [Abstract][Full Text] [Related]
19. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
